Chris Jericho, Kota Ibushi? Both teams need a fifth man.
While Jericho hasn't been part of the BCC vs Elite feud, he was in the past two Blood and Guts matches so he at least has ample experience.
A name less familiar to AEW fans is Homicide, who did appear on Grand Slam in 2021, aiding Moxley and Eddie Kingston after their match with Lance Archer and Minoru Suzuki. Homicide and Moxley have plenty of history and teamed together earlier this month on NJPW Strong. Another name fans have speculated on is Chris Hero, whoHero previously teamed with Claudio as the Kings of Wrestling and has been working backstage at AEW recently. A fan on Twitter recently told AEW CEO Tony Khan to: "Get Chris Hero in that cage," to whichAnother potential recruit for the BCC is Will Ospreay who recently had an epic match with Omega at Forbidden Door.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Scots man who sprayed cops with blood as they tried to arrest him jailedTwo police officers endured months of medical tests after their faces were sprayed with blood as they tried to arrest a man
Read more »
Drum solos and one-handed bass riffs: Royal Blood impress at TRNSMT'Thank you so much, have a great f***ing festival.' royalblooduk TRNSMTfest 📸Colin Mearns MearnsColin Review: MorganCarmicha9
Read more »
Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study - BMC SurgeryBackground Emergency laparotomy (EmLAP) is one of the commonest emergency operations performed in the United Kingdom (approximately 30, 000 laparotomies annually). These potentially high-risk procedures can be life changing with frail patients and/ or older adults (≥ 65 years) having the poorest outcomes, including mortality. There is no gold standard of frailty assessment and no clinical chemical biomarkers existing in practice. Early detection of subclinical changes or deficits at the molecular level are essential in improving our understanding of the biology of frailty and ultimately improving patient outcomes. This study aims primarily to compare preoperative frailty markers, including a blood-based biomarker panel, in their ability to predict 30 and 90-day mortality post-EmLAP. The secondary aim is to analyse the influence of perioperative frailty on morbidity and quality of life post-EmLAP. Methods A prospective single centred observational study will be conducted on 150 patients ≥ 40 years of age that undergo EmLAP. Patients will be included according to the established NELA (National Emergency Laparotomy Audit) criteria. The variables collected include demographics, co-morbidities, polypharmacy, place of residence, indication and type of surgery (as per NELA criteria) and prognostic NELA score. Frailty will be assessed using: a blood sample for ultra-high performance liquid chromatography mass spectrometry analysis; preoperative CT abdomen pelvis (sarcopenia) and Rockwood Clinical Frailty Scale (CFS). Patients will be followed up for 90 days. Variables collected include blood samples (at post operative day 1, 7, 30 and 90), place of residence on discharge, morbidity, mortality and quality of life (EQ-5D-5 L). The frailty markers will be compared between groups of frail (CFS ≥ 4) and non-frail using statistical methods such as regression model and adjusted for appropriate confounding factors. Discussion This study hypothesises that frailty level changes follo
Read more »
JonBenét confessor sent classmate 'bloody tapes, hair sample & missing poster'A SUSPECT in the unsolved killing of JonBenét Ramsey is a “serial creep” who mailed an old high school classmate blood-stained cassettes containing disturbing recordings and newspaper c…
Read more »
TRNSMT 2023 LIVE updates from final day as The 1975 set to performIt's day three of the festival and audiences are in for a real treat today with The 1975, Royal Blood and Becky Hill among the brilliant acts all set to perform.
Read more »
SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI - BMC Cardiovascular DisordersBackground Taking statins for a long time is associated with an increased risk of new-onset diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce insulin resistance and improve pancreatic β-cell function. Methods and results In total, 333 non-diabetes patients with heart failure with reduced ejection fraction (HFrEF) after percutaneous coronary intervention (PCI) are included. The enrolled patients are divided into a matched group (n = 198) and an SGLT2 inhibitors group (n = 135). There are no statistical differences in general information between the two groups before treatment. After a mean follow-up time of 13 months, abnormal blood glucose levels are significantly higher in the matched group than in the SGLT2 inhibitors group (6.06 vs. 0.74%, P | 0.05). There are no statistically significant differences in the alanine aminotransferase (ALT), uric acid (UA), and estimated glomerular filtration (eGFR) levels between the two groups. Conclusion SGLT2 inhibitors play a significant protective role in reducing the risk of statins-induced abnormal blood glucose in non-diabetes patients with HFrEF after PCI, without increasing the burden on the heart, kidneys, and liver.
Read more »